Login / Signup

Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma.

Xianbin WuRunkun HanYanping ZhongNuoqing WengAo Zhang
Published in: Cancer cell international (2021)
NLR at 6 weeks post treatment is a predictor of the response to anti-PD-1 treatment in patients with ESCC.
Keyphrases
  • stem cells
  • bone marrow
  • mesenchymal stem cells
  • smoking cessation